Joan Lunden discusses the diagnostic approach that led to the early detection of triple-negative breast cancer, which was undetected by mammogram and 3D mammogram but was detected with ultrasound.
Joan Lunden discusses the diagnostic approach that led to the early detection of triple-negative breast cancer, which was undetected by mammogram and 3D mammogram but was detected with ultrasound.
Lunden recounts an interview with Susan M. Love, MD, where she discovered the need for ultrasound, as a result of her dense breast tissue. It was this revelation and procedure that greatly impacted the stage of disease at diangosis and overall prognosis, Lunden says.
Joan Lunden will be delivering the keynote address at the32nd Miami Breast Cancer Conference.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More